(Reuters) – Mylan NV (O:) reported a 7.4% rise in third-quarter profit on Tuesday, as the generic drugmaker benefited from new product launches.
The company, which in July said it would merge with Pfizer Inc’s (N:) off-patent branded drugs unit, said net earnings rose to $189.8 million, or 37 cents per share, in the quarter ended Sept 30 from $176.7 million, or 34 cents per share, a year earlier.
Total revenue rose to $2.96 billion from $2.86 billion.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.